Biomarker that predicts response to hepatitis C treatment identified
Monday, August 17th, 2009LONDON - Duke University Medical Center scientists have discovered the first genetic marker that predicts response to hepatitis C treatments.
LONDON - Duke University Medical Center scientists have discovered the first genetic marker that predicts response to hepatitis C treatments.
Gene variant predicts hepatitis treatment success
NEW YORK — Scientists say they’ve found a big reason why treatment for chronic hepatitis C infection works better for white patients than for African-Americans. It’s a tiny variation in a gene.
WASHINGTON - Experts at Heidelberg University Hospital in Germany say that they have identified a protein in infected liver cells that is essential for the replication of the hepatitis C virus (HCV).
NEW DELHI - Medicinal herbs like tulsi, which is commonly found in people’s homes, can help boost one’s immunity and thus fight Influenza A (H1N1), say Ayurveda doctors.
Anadys says hepatitis C drug shows potential
SAN DIEGO — Anadys Pharmaceuticals Inc. said Tuesday its hepatitis C drug candidate ANA-773 could be extremely effective at treating the diseases.
WASHINGTON - Blueberry leaves might offer protection against hepatitis C virus infections, according to researchers.
WASHINGTON - A volunteer has for the first time received a human monoclonal antibody that can neutralize the Hepatitis C virus (HCV).
New HIV strain discovered in woman from Cameroon
WASHINGTON — A new strain of the virus that causes AIDS has been discovered in a woman from the African nation of Cameroon.
Anadys rockets after FDA approves trial design
NEW YORK — Shares of Anadys Pharmaceuticals Inc. climbed Friday after the company said regulators approved the design of a study of a potential hepatitis C treatment.
Anadys gets FDA OK to start hepatitis C study
SAN DIEGO — Anadys Pharmaceuticals Inc. said Thursday the Food and Drug Administration cleared the company’s plan for a midstage study on a potential combination therapy for hepatitis C.